[ad_1]
This decision was made in six cases of “rare and complex” blood clots in the United States.
A total of 6.8 million have already been vaccinated in the country. Blood clots formed after six doses of the Johnson & Johnson vaccine and six vaccines. All six cases involved women ages 18 to 48 who developed symptoms 6 to 13 days after vaccination.
The U.S. Centers for Disease Control and Prevention is urgently convening a meeting of the Advisory Committee on Immunization Practices on Wednesday to review clot cases and assess potential risks, according to the report.
“The US Food and Drug Administration will review the findings of the case studies. Until the process is complete, we recommend discontinuing this vaccine for safety reasons. This is in part important to ensure that the entire health system is informed about these cases, ready to take action if necessary, and to identify and neutralize risks in a timely manner, ”the document adds.
The Johnson & Johnson single-dose vaccine against coronavirus infection was approved by US authorities in late February.
The vaccine was then reported to be highly effective in clinical trials in the United States, South Africa, and Brazil, with more than 85% effective in preventing severe COVID-19 and an overall effectiveness of 66% in including moderate cases.
Last Friday, the main US pharmaceutical watchdog said it had not yet found a “causal” link between the vaccine developed by Johnson & Johnson and the rare cases of blood clots in people who received the drug. medicine.
“We have not yet established a causal relationship with vaccination and we continue to investigate these cases,” the US Food and Drug Administration (FDA) said in a statement.
The agency said it was aware of “several people” in the United States who had blood clots and had low platelet counts when they were vaccinated with Johnson & Johnson.
“Both disorders can have many different causes,” the FDA emphasized. “We will keep the public informed as we learn more.”
At the time, the European Medicines Agency (EMA) reported receiving four cases of blood clots and thrombocytopenia after an injection of the Johnson & Johnson vaccine. One of these cases resulted in the death of the patient.
The EEA also said it was investigating these incidents.
The EU has allowed the use of the Johnson & Johnson vaccine, but vaccination with it in the Community should only start at the end of this month. The study began a few days after the EVA stated that abnormal blood clots should be labeled a “very rare” side effect of the AstraZeneca pandemic coronavirus vaccine.
Both vaccines were developed using similar adenovirus vector technology.
The Johnson & Johnson maker began supplying the vaccine to the Community on Monday, the European Commission confirmed in Brussels.
By the end of June, the EU expects 55 million doses of this vaccine. One dose of Johnson & Johnson vaccine is enough to give a person full immunity against COVID-19. The other three vaccines registered in the EU require two doses.
Therefore, countries have high hopes that this will accelerate the vaccination campaign. The vaccine, developed by Johnson & Johnson’s subsidiary Janssen in the Netherlands, is the fourth vaccine registered in the EU.
In the US it has been used for some time.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to indicate DELFI as the source .
[ad_2]
